Kolon TissueGene starts Phase III clinical trial for ‘Invossa’

Kolon TissueGene(CEO Bum-Seop Lee & Woo-Seok Lee) announced on the 6^th that they acquired the Chemistry, Manufacturing and Controls(CMC) from the U.S. FDA and would start a Phase III clinical trial in the U.S.

Kolon TissueGene acquired approval of the Phase III clinical trial on May 2015 and has taken a process of getting the CMC by following standards suggested by the U.S. FDA. As getting the...